Real-world efficacy and safety of inetetamab-based therapy in HER2-positive metastatic breast cancer patients with prior exposure to trastuzumab.

ABSTRACT:

Background

Until now there has been no comprehensive data from extensive samples to evaluate the therapeutic potential of inetetamab in metastatic breast cancer (MBC) patients who had a history of trastuzumab treatment. Some previous studies had either small sample sizes from single-center, or partial enrolled patients without prior exposure to trastuzumab. This study aimed to provide a deep analysis of inetetamab-based therapy in this specific population.

Methods

A multicenter retrospective study collected clinicopathological data from a total of 500 patients between Jul 2020 and Oct 2023. Progression-free survival (PFS) was estimated as the primary endpoint. Secondary endpoints included objective response rate (ORR), disease control rate (DCR) and adverse events (AEs). The

SUBMITTER: Duan Y 

PROVIDER: S-EPMC12436387 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature